Zonisamide Therapy Reduces Metabolic Consequences and Diminishes Nonalcoholic Fatty Liver Disease in Patients with Epilepsy
Antiepileptic drugs that can reduce aberrant metabolism are beneficial for patients. Zonisamide (ZNS) is a chemical with antiepileptic and antioxidant activities. Here, we evaluate the efficacy of ZNS therapy on reducing obesity and decreasing risks of vascular diseases and hepatic steatosis. Clinic...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-07-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/10/15/3380 |
| _version_ | 1797525455921741824 |
|---|---|
| author | Chi-Ren Huang Hung-Yi Chuang Nai-Ching Chen Shu-Fang Chen Chung-Yao Hsu Yao-Chung Chuang |
| author_facet | Chi-Ren Huang Hung-Yi Chuang Nai-Ching Chen Shu-Fang Chen Chung-Yao Hsu Yao-Chung Chuang |
| author_sort | Chi-Ren Huang |
| collection | DOAJ |
| description | Antiepileptic drugs that can reduce aberrant metabolism are beneficial for patients. Zonisamide (ZNS) is a chemical with antiepileptic and antioxidant activities. Here, we evaluate the efficacy of ZNS therapy on reducing obesity and decreasing risks of vascular diseases and hepatic steatosis. Clinical and metabolic indicators including body weight, body mass index (BMI), serum lipid profiles, glycated hemoglobin (HbA1c), homocysteine, and an inflammatory marker, high-sensitivity C-reactive protein (hs-CRP), were assessed at baseline and at the end of 12 and 24 weeks of treatment. Nonalcoholic fatty liver disease was evaluated using the hepatic steatosis index (HSI). A body weight reduction of ≥5% was observed in 24.6% and 32.8% of patients after 12 and 24 weeks of ZNS treatment, respectively. After adjusting for age, sex, time, and the corresponding dependent variable at baseline, the generalized estimating equation analysis revealed that the body weight, BMI, serum levels of HbA1c, triglycerides, hs-CRP, and the index for HSI were significantly declined. These results suggest that ZNS provides benefits in patients with obesity and metabolic syndrome at high vascular risk. |
| first_indexed | 2024-03-10T09:13:06Z |
| format | Article |
| id | doaj.art-8aee4dd95a944148b921eb1bf64bb6d9 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T09:13:06Z |
| publishDate | 2021-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-8aee4dd95a944148b921eb1bf64bb6d92023-11-22T05:49:55ZengMDPI AGJournal of Clinical Medicine2077-03832021-07-011015338010.3390/jcm10153380Zonisamide Therapy Reduces Metabolic Consequences and Diminishes Nonalcoholic Fatty Liver Disease in Patients with EpilepsyChi-Ren Huang0Hung-Yi Chuang1Nai-Ching Chen2Shu-Fang Chen3Chung-Yao Hsu4Yao-Chung Chuang5Department of Neurology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 83301, TaiwanDepartment of Public Health and Environmental Medicine, College of Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 80708, TaiwanDepartment of Neurology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 83301, TaiwanDepartment of Neurology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 83301, TaiwanDepartment of Neurology, School of Medicine, College of Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 80708, TaiwanDepartment of Neurology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 83301, TaiwanAntiepileptic drugs that can reduce aberrant metabolism are beneficial for patients. Zonisamide (ZNS) is a chemical with antiepileptic and antioxidant activities. Here, we evaluate the efficacy of ZNS therapy on reducing obesity and decreasing risks of vascular diseases and hepatic steatosis. Clinical and metabolic indicators including body weight, body mass index (BMI), serum lipid profiles, glycated hemoglobin (HbA1c), homocysteine, and an inflammatory marker, high-sensitivity C-reactive protein (hs-CRP), were assessed at baseline and at the end of 12 and 24 weeks of treatment. Nonalcoholic fatty liver disease was evaluated using the hepatic steatosis index (HSI). A body weight reduction of ≥5% was observed in 24.6% and 32.8% of patients after 12 and 24 weeks of ZNS treatment, respectively. After adjusting for age, sex, time, and the corresponding dependent variable at baseline, the generalized estimating equation analysis revealed that the body weight, BMI, serum levels of HbA1c, triglycerides, hs-CRP, and the index for HSI were significantly declined. These results suggest that ZNS provides benefits in patients with obesity and metabolic syndrome at high vascular risk.https://www.mdpi.com/2077-0383/10/15/3380zonisamideepilepsyobesitymetabolic consequencesnonalcoholic fatty liver disease |
| spellingShingle | Chi-Ren Huang Hung-Yi Chuang Nai-Ching Chen Shu-Fang Chen Chung-Yao Hsu Yao-Chung Chuang Zonisamide Therapy Reduces Metabolic Consequences and Diminishes Nonalcoholic Fatty Liver Disease in Patients with Epilepsy Journal of Clinical Medicine zonisamide epilepsy obesity metabolic consequences nonalcoholic fatty liver disease |
| title | Zonisamide Therapy Reduces Metabolic Consequences and Diminishes Nonalcoholic Fatty Liver Disease in Patients with Epilepsy |
| title_full | Zonisamide Therapy Reduces Metabolic Consequences and Diminishes Nonalcoholic Fatty Liver Disease in Patients with Epilepsy |
| title_fullStr | Zonisamide Therapy Reduces Metabolic Consequences and Diminishes Nonalcoholic Fatty Liver Disease in Patients with Epilepsy |
| title_full_unstemmed | Zonisamide Therapy Reduces Metabolic Consequences and Diminishes Nonalcoholic Fatty Liver Disease in Patients with Epilepsy |
| title_short | Zonisamide Therapy Reduces Metabolic Consequences and Diminishes Nonalcoholic Fatty Liver Disease in Patients with Epilepsy |
| title_sort | zonisamide therapy reduces metabolic consequences and diminishes nonalcoholic fatty liver disease in patients with epilepsy |
| topic | zonisamide epilepsy obesity metabolic consequences nonalcoholic fatty liver disease |
| url | https://www.mdpi.com/2077-0383/10/15/3380 |
| work_keys_str_mv | AT chirenhuang zonisamidetherapyreducesmetabolicconsequencesanddiminishesnonalcoholicfattyliverdiseaseinpatientswithepilepsy AT hungyichuang zonisamidetherapyreducesmetabolicconsequencesanddiminishesnonalcoholicfattyliverdiseaseinpatientswithepilepsy AT naichingchen zonisamidetherapyreducesmetabolicconsequencesanddiminishesnonalcoholicfattyliverdiseaseinpatientswithepilepsy AT shufangchen zonisamidetherapyreducesmetabolicconsequencesanddiminishesnonalcoholicfattyliverdiseaseinpatientswithepilepsy AT chungyaohsu zonisamidetherapyreducesmetabolicconsequencesanddiminishesnonalcoholicfattyliverdiseaseinpatientswithepilepsy AT yaochungchuang zonisamidetherapyreducesmetabolicconsequencesanddiminishesnonalcoholicfattyliverdiseaseinpatientswithepilepsy |